Procter & Gamble Health Ltd
Procter & Gamble Health Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The company has delivered consistent high single-digit sales growth over the past 5 years despite market volatility and operational changes. Company has delivered consistent high single digit sales growth (~8%) and average profit growth of 9% over past 5 years. - Net profit margin expanded by 200 basis points over past 5 years. - Return on equity increased 3 times during this period, reflecting resilience and execution. - Fiscal year ended March 31, 2025 reported profit after tax of Rs.
From Procter & Gamble Health Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company has delivered consistent high single-digit sales growth over the past 5 years despite market volatility and operational changes.
- They achieved strong single-digit top-line growth and double-digit bottom-line growth in the recent fiscal year.
- Focus remains on increasing penetration in categories like Nerve Care, Vitamin E, and Nasal Decongestant with market leadership in Vitamin E.
- There is significant runway for growth by serving unserved and underserved healthcare practitioners (HCPs) and consumers.
- The integrated growth strategy combining product superiority, retail execution, and HCP engagement is viewed as the right approach to sustain growth.
- Export markets, such as Sri Lanka, show strong potential with over 30% growth recently.
2 more points from Procter & Gamble Health Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Procter & Gamble Health Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The transcript does not explicitly mention any current or future capital expenditure (capex) or strategic investments.
- The company emphasizes ongoing investments in raising superiority standards across product formulations, packaging, communication, and retail execution to serve consumer needs better.
- Productivity efforts (achieving savings of over Rs. 40 crore this fiscal) are highlighted as fuel to reinvest in superiority across five vectors.
- There is a focus on investments to improve products and launch new superior products, as well as investing in capabilities and innovative go-to-market models.
- They invest in healthcare practitioner engagement and collaborations with healthcare organizations to create a holistic ecosystem.
2 more points from Procter & Gamble Health Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Procter & Gamble Health Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Procter & Gamble Health Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Procter & Gamble Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹370 Cr, net profit ₹95 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What P & G Health Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Procter & Gamble Health Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Procter & Gamble Health Ltd Q4 FY25 results?
The company has delivered consistent high single-digit sales growth over the past 5 years despite market volatility and operational changes. Company has delivered consistent high single digit sales growth (~8%) and average profit growth of 9% over past 5 years. - Net profit margin expanded by 200 basis points over past 5 years. - Return on equity increased 3 times during this period, reflecting resilience and execution. - Fiscal year ended March 31, 2025 reported profit after tax of Rs.
What is Procter & Gamble Health Ltd share price analysis?
Procter & Gamble Health Ltd currently shows a neutral. The stock trades at a P/E of 32.8 with a market cap of ₹10,731 Cr. Investors should review the full earnings analysis for detailed insights.
Is Procter & Gamble Health Ltd planning capital expenditure?
The transcript does not explicitly mention any current or future capital expenditure (capex) or strategic investments. - The company emphasizes ongoing investments in raising superiority standards across product formulations, packaging, communication, and retail execution to serve consumer needs better. - Productivity efforts (achieving savings of over Rs.
Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.